Investigation of Galcanezumab for Migraine Prevention
Understanding Migraines
Migraines are chronic and debilitating headaches that can persist for hours or even days. The impact on those affected is significant, resulting in absenteeism from both work and school, as well as a notable loss of productivity. Many patients discontinue their migraine treatments due to insufficient efficacy or adverse side effects, highlighting the need for new therapeutic options to provide relief.
Overview of Galcanezumab
Galcanezumab is a monoclonal antibody designed to target calcitonin gene-related peptide (CGRP), a protein that has been shown to be elevated in individuals suffering from migraines. CGRP is believed to play a crucial role in the development of migraine pathology. Previous phase two trials indicated that galcanezumab is both effective and safe for migraine prevention.
Recent Clinical Trials
Researchers associated with Eli Lilly, the developers of galcanezumab, conducted another phase two trial to determine the most effective dosage for preventing migraines. The findings were published recently in the journal JAMA Neurology.
In the trial, 410 participants received either galcanezumab or a placebo in four different doses (5 mg, 50 mg, 120 mg, or 300 mg). To evaluate the treatment’s efficacy, participants completed two questionnaires: the Migraine-Specific Quality of Life and the Headache Impact Test-6. Each participant received monthly subcutaneous injections for three months, followed by a three-month follow-up period without any active drug or placebo.
Key Study Findings
The primary goal of the study was to identify which dose of galcanezumab was more effective than the placebo in preventing migraines. The results indicated that both the 120 mg and 300 mg doses significantly reduced the number of migraine headache days. Notably, the 120 mg dose was the lowest to show superiority over the placebo.
Interestingly, the placebo response rate in this study was higher than the typical 30%, likely due to participants’ expectations of receiving an effective new treatment.
Side Effects and Tolerability
The side effect profile for galcanezumab appeared to be favorable. Commonly reported side effects included injection-site pain, upper respiratory tract infections, painful menstrual cramps, and nausea, all of which were described as mild to moderate in intensity.
Conclusion and Future Directions
The demand for safe and effective preventative treatments for migraines is substantial among those affected. Galcanezumab demonstrates high target specificity, contributing to its effectiveness and safety. However, further long-term studies conducted by independent researchers are necessary to validate these preliminary findings.
Reference
Skljarevski V, Oakes TM, Zhang Q, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2017.